Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern
Anupriya Aggarwal, Anouschka Akerman, Vanessa Milogiannakis, et al.
EBioMedicine (2022) Vol. 84, pp. 104270-104270
Open Access | Times Cited: 138

Showing 1-25 of 138 citing articles:

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway
Brian J. Willett, Joe Grove, Oscar A. MacLean, et al.
Nature Microbiology (2022) Vol. 7, Iss. 8, pp. 1161-1179
Open Access | Times Cited: 531
Evolution of the SARS‐CoV‐2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission
Lok Bahadur Shrestha, Charles S. P. Foster, William D. Rawlinson, et al.
Reviews in Medical Virology (2022) Vol. 32, Iss. 5
Open Access | Times Cited: 406
Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5
Izumi Kimura, Daichi Yamasoba, Tomokazu Tamura, et al.
Cell (2022) Vol. 185, Iss. 21, pp. 3992-4007.e16
Open Access | Times Cited: 238
Monoclonal antibody therapies against SARS-CoV-2
Daniele Focosi, Scott A. McConnell, Arturo Casadevall, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 11, pp. e311-e326
Open Access | Times Cited: 204
Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning?
Christoph Jung, Dorota Kmieć, Lennart Koepke, et al.
Journal of Virology (2022) Vol. 96, Iss. 6
Open Access | Times Cited: 203
Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis
Kaiming Tao, Philip L. Tzou, Sergei L. Kosakovsky Pond, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 4
Open Access | Times Cited: 76
Determinants of Spike infectivity, processing, and neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2
Chiara Pastorio, Fabian Zech, Sabrina Noettger, et al.
Cell Host & Microbe (2022) Vol. 30, Iss. 9, pp. 1255-1268.e5
Open Access | Times Cited: 74
Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant
Hao Zhou, Michelle Møhlenberg, Jigarji Chaturji Thakor, et al.
Clinical Microbiology Reviews (2022) Vol. 35, Iss. 3
Open Access | Times Cited: 67
Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China
Liyan Yang, Zhonglei Wang
European Journal of Medicinal Chemistry (2023) Vol. 257, pp. 115503-115503
Open Access | Times Cited: 63
Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level
Anouschka Akerman, Vanessa Milogiannakis, Tyra Jean, et al.
EBioMedicine (2023) Vol. 90, pp. 104545-104545
Open Access | Times Cited: 44
Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies
Timothée Bruel, Karl Stéfic, Yann Nguyen, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 12, pp. 100850-100850
Open Access | Times Cited: 54
Sotrovimab: First Approval
Young‐A Heo
Drugs (2022) Vol. 82, Iss. 4, pp. 477-484
Open Access | Times Cited: 53
In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate
Franck Touret, Cécile Baronti, Hawa Sophia Bouzidi, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 52
An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern
Wenjuan Du, Daniel L. Hurdiss, Dubravka Drabek, et al.
Science Immunology (2022) Vol. 7, Iss. 73
Open Access | Times Cited: 51
The Impact of Vaccination on Incidence and Outcomes of SARS-CoV-2 Infection in Patients with Kidney Failure in Scotland
Samira Bell, Jacqueline Campbell, Emilie Lambourg, et al.
Journal of the American Society of Nephrology (2022) Vol. 33, Iss. 4, pp. 677-686
Open Access | Times Cited: 51
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
Zhenhao Fang, Lei Peng, Renata B. Filler, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 50
COVID-19 and pregnancy: clinical outcomes; mechanisms, and vaccine efficacy
Deepak Kumar, Sonam Verma, Indira U. Mysorekar
Translational research (2022) Vol. 251, pp. 84-95
Open Access | Times Cited: 46
Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant
Kevin K. Ariën, Leo Heyndríckx, Johan Míchiels, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 44
SARS‐CoV‐2 Omicron and its current known unknowns: A narrative review
Trang Thi Bich Le, Tamilarasy Vasanthakumaran, Nguyen Thi Hien Hau, et al.
Reviews in Medical Virology (2022) Vol. 33, Iss. 1
Open Access | Times Cited: 41
The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies
Daniele Focosi, Scott A. McConnell, Arturo Casadevall
Drug Resistance Updates (2022) Vol. 65, pp. 100882-100882
Open Access | Times Cited: 40
Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life
Luca Cegolon, Riccardo Pol, Omar Simonetti, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 5, pp. 721-721
Open Access | Times Cited: 35
The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5
Huiping Shuai, Jasper Fuk‐Woo Chan, Bingjie Hu, et al.
EBioMedicine (2023) Vol. 95, pp. 104753-104753
Open Access | Times Cited: 35
Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants
Amin Addetia, Luca Piccoli, James Brett Case, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 30
Omicron subvariant BA.5 efficiently infects lung cells
Markus Hoffmann, Lok-Yin Roy Wong, Prerna Arora, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 30
Omicron Variant of SARS-CoV-2: An Indian Perspective of Vaccination and Management
Vivek P. Chavda, Pankti C. Balar, Dixa A. Vaghela, et al.
Vaccines (2023) Vol. 11, Iss. 1, pp. 160-160
Open Access | Times Cited: 28
Page 1 - Next Page

Scroll to top